IN THE MANAGEMENT OF TYPE 2 DIABETES*1
THE POWER TO
ACCOMPLISH
MORE
ACCOMPLISH
MORE
MULTIPLE BENEFITS.* PROVEN PROTECTION.†
What makes SGLT2i an ideal HF therapy?
17/04/2024 | Author: Boehringer Ingelheim
Click on the timestamp to jump to the topic you are interested in.
| Effect of SGLT2i on the kidneys | ||
| EMPEROR-Reduced: Effect of empagliflozin on the adjusted mean change in eGFR from randomization | ||
| EMPEROR-Reduced: Empagliflozin protected the kidney by slowing the progression of kidney disease | ||
| EMPEROR-Preserved: Empagliflozin protected the kidney by significantly slowing the decline in kidney function | ||
Document ID: PC-MY-102951
RELATED CONTENT
4:27
PTPHF||What is the role of empagliflozin in patients hospitalized for heart failure?
2:48
PTPHF||What do we know about the consistency of the results for empagliflozin across the spectrum of ejection fraction?
2:26
